Week in Washington 020124

Week in Washington is brought to you by Michael Cohen, PhD. Tune in each week to read the latest on healthcare policy and get a glimpse of what’s on the horizon.

Week in Washington


Advance Notice Released

CMS released its annual proposed (2025) Advance Notice yesterday. Within the Annual Notice, CMS proposed a reduction in base payments. The reduction primarily is because of the phase in the changes to the risk adjustment coding system. The fact sheet can be found here. There is a large amount of pressure from Congressional Democrats to reduce payments to MA plans.

First Price Offers

CMS is expected to announce today (February 1st) the first drug negotiation offers to the 10 drugs selected for negotiation. There are a number of key unknowns as how CMS might approach its first ever drug negotiation and the initial offer will shed light on this.


Biogen announced that it is discontinuing its controversial Alzheimer’s drug Aduhelm. Aduhelm was once projected as a huge seller with potentially seismic impacts to the drug market. However, uptake and approval never fully materialized which culminated in this week’s announcement.

More Medicaid Expansion?

Politico reported that there is some momentum in certain Southern states to consider expanding Medicaid. Alabama, Georgia, and Mississippi have all had state-level conversations and potential movement towards Medicaid Expansion in the coming legislative cycle. There are currently 10 states that have not expanded Medicaid.

Previous editions: 

01/26/2024: Week in Washington

01/18/2024: Week in Washington

01/11/2024: Week in Washington

01/04/2024: Week in Washington


12/14/2023: Week in Washington

12/07/2023: Week in Washington

11/30/2023: Week in Washington

11/16/2023: Week in Washington

Read More Wakely Insights
©2017-2024 Wakely Consulting Group LLC  All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Wakely Consulting Group. Wakely does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of this information is voluntary.